Inventiva SA banner

Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 5.11 EUR -1.73% Market Closed
Market Cap: €1.1B

Inventiva SA
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Inventiva SA
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Inventiva SA
PAR:IVA
Other
€129m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other
-€19m
CAGR 3-Years
-27%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other
-€7.9m
CAGR 3-Years
-57%
CAGR 5-Years
0%
CAGR 10-Years
-58%
DBV Technologies SA
PAR:DBV
Other
-$345k
CAGR 3-Years
8%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Abivax SA
PAR:ABVX
Other
-€12.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sensorion SA
PAR:ALSEN
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inventiva SA
Glance View

Market Cap
1.1B EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
0.48 EUR
Overvaluation 91%
Intrinsic Value
Price

See Also

What is Inventiva SA's Other?
Other
118.5m EUR

Based on the financial report for Jun 30, 2025, Inventiva SA's Other amounts to 118.5m EUR.

What is Inventiva SA's Other growth rate?
Other CAGR 1Y
2 224%

Over the last year, the Other growth was 2 224%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett